Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma

被引：0
|
作者：
Ciesielski, Michael J.
Ahluwalia, Manmeet Singh
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Peereboom, David M.
Figel, Sheila A.
Hutson, Alan
Groman, Adrienne
Withers, Henry G.
Liu, Song
Belal, Ahmed
Qiu, Jing-Xin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle M.
Mechtler, Laszlo
Fenstermaker, Robert Alan
机构：
[1] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[2] Taussig Canc Inst, Neurol Inst, Rose Ella Burkhardt Brain Tumor & Neuro Oncol Ctr, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Massachusetts Gen Hosp, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA USA
[8] MimiVax, Buffalo, NY USA
[9] Dent Neurol Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2037
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
    Costa, Luciano J.
    Chhabra, Saurabh
    Medvedova, Eva
    Dholaria, Bhagirathbhai R.
    Schmidt, Timothy M.
    Godby, Kelly N.
    Silbermann, Rebecca
    Dhakal, Binod
    Bal, Susan
    Giri, Smith
    D'Souza, Anita
    Hall, Aric C.
    Hardwick, Pamela
    Omel, James
    Cornell, Robert F.
    Hari, Parameswaran
    Callander, Natalie S.
    LANCET HAEMATOLOGY, 2023, 10 (11): : e890 - e901
  • [12] Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial
    Liu, Jing
    Hu, Dan
    Li, Li
    Zang, Lele
    Zhu, Fei
    Zhu, Mingxuan
    Zhang, Huiqi
    Chang, Lele
    Xu, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [13] Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients
    Nicholas, Martin Kelly
    Lukas, Rimas Vincas
    Amidei, Christine
    Vick, Nicholas
    Paleologos, Nina
    Malkin, Mark Gordon
    Krouwer, Hendrikus
    Junck, Larry
    Arzbaecher, Jean
    Lai, Albert
    Merrell, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)
    Ahluwalia, Manmeet
    Ciesielski, Michael J.
    Abad, Ajay
    Reardon, David A.
    Aiken, Robert
    Barbaro, Marissa
    Sinicrope, Kaylyn
    Peereboom, David
    Odia, Yazmin
    Brenner, Andrew
    Venur, Vyshak
    Belal, Ahmed
    Qiu, Jingxin
    Khosla, Atulya
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [15] A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).
    Ahluwalia, Manmeet Singh
    Ciesielski, Michael J.
    Reardon, David A.
    Butowski, Nicholas A.
    Aiken, Robert
    Venur, Vyshak
    Abad, Ajay Prakash
    Mechtler, Laszlo
    Peereboom, David M.
    Odia, Yazmin
    Sinicrope, Kaylyn
    Boockvar, John A.
    Brenner, Andrew J.
    Barbaro, Marissa
    Ozair, Ahmad
    Belal, Ahmed
    Qiu, Jing-Xin
    Khosla, Atulya Aman
    Casucci, Danielle M.
    Fenstermaker, Robert Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [16] Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
    Zhou, De
    Huang, Xianbo
    Li, Xueying
    Zhu, Lixia
    Xie, Mixue
    Huang, Xin
    Yu, Fang
    Wei, Juying
    Ma, Liya
    Yang, Xiudi
    Sun, Jianai
    Li, Li
    Xie, Wanzhuo
    Tong, Hongyan
    Jin, Jie
    Zhu, Honghu
    Ye, Xiujin
    BLOOD, 2022, 140 : 2620 - 2621
  • [17] A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
    Ahluwalia, Manmeet
    Ciesielski, Michael
    Abad, Ajay
    Reardon, David
    Ozair, Ahmad
    Khosla, Atulya
    Aiken, Robert
    Barbaro, Marissa
    Sinicrope, Kaylyn
    Peereboom, David
    Odia, Yazmin
    Brenner, Andrew
    Venur, Vyshak
    Belal, Ahmed
    Qiu, Jingxin
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2024, 26
  • [18] Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
    Lin, Jieping
    Huang, Zicong
    Cai, Zihong
    Li, Jia
    Li, Zhen
    Ding, Chenhao
    Wang, Zhixiang
    Li, Xiaofang
    Zhou, Xuan
    He, Bailin
    Zhong, Wenhao
    Xuan, Li
    Liu, Qifa
    Xu, Yang
    Zhou, Hongsheng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [19] Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
    O'Donnell, Elizabeth
    Mo, Clifton
    Yee, Andrew J.
    Nadeem, Omar
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Munshi, Nikhil
    Midha, Shonali
    Cirstea, Diana
    Chrysafi, Pavlina
    Horick, Nora
    Richardson, Paul G.
    Raje, Noopur
    LANCET HAEMATOLOGY, 2024, 11 (06): : e415 - e424
  • [20] Nimotuzumab and bevacizumab combined with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme: a retrospective single-arm study
    Wu, Yaping
    Chen, Zhiying
    Shi, Mingtao
    Qiu, Shuo
    Zhang, Yongchun
    JOURNAL OF NEURO-ONCOLOGY, 2025, : 429 - 436
12345